Conference Proceedings
Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study
Constantine S Tam, Edmund K Waller, Ulrich Jaeger, Isabelle Fleury, Joseph McGuirk, Harald Holte, Samantha Jaglowski, Stephen J Schuster, Michael R Bishop, Jason R Westin, Takanori Teshima, Veronika Bachanova, Stephen Ronan Foley, Peter Borchmann, Gilles A Salles, Oezlem Anak, Jie Zhang, Ranjan Tiwari, Lida B Pacaud, Qiufei Ma Show all
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | ELSEVIER SCIENCE INC | Published : 2019
Abstract
Background Quality of life (QoL) is an important endpoint in the JULIET study (NCT02445248), a phase 2 trial evaluating a single infusion of tisagenlecleucel in adult patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Earlier analyses showed improvements in QoL at month (mo) 3 and 6 (Maziarz et al, ASH 2017, EBMT 2018). We report updated JULIET data with extended follow-up (FU; median: 19.3 mo). Methods Pts were aged ≥18 years with r/r DLBCL after ≥2 lines of therapy and either failed or were ineligible for autologous hematopoietic stem cell transplant (SCT). At baseline, mo-3 through mo-24, pts completed the Functional Assessment of Cancer Therapy-Lymphoma ..
View full abstract